Quince Therapeutics Inc. (QNCX) Fundamentals

Cortexyme Inc is a clinical-stage biopharmaceutical company developing a disease-modifying therapeutic approach to treat Alzheimer's and other degenerative diseases. Its approach is based on the seminal discovery of the presence of Porphyromonas gingivalis or P. gingivalis, and its secreted toxic virulence factor proteases called gingipains. The company operates in only one reportable segment that is developing and commercializing therapeutics.
SHARE INFORMATION
Market CapUS$ 48,018,493
Shares Outstanding36,104,130
Float25,443,109
Percent Float70.47%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per ShareUS$ 0.00
Latest Fiscal RevenueUS$ 0
Latest Fiscal EPSUS$ -3.03
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)US$ 0.00
Dividend (5 Years)US$ 0.00
Ex Dividend Date-
Dividend RateUS$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions255
Institutional Holdings Date2022-08-31
Institutional Bought Previous 3 Months1,296,784
Institutional Holdings Percent54.6%
Institutional Sold Previous 3 Months10,126,384
Insider Holdings Date2022-08-31
Insider Bought Previous 3 Months412,000
Insider Holdings Percent6.9
Insider Sold Previous 3 Months29,949
Insider Shares Owned2,481,360
TRADING INFO
52 Week HighUS$ 98.50
52 Week LowUS$ 1.20
52 Week High ChangeUS$ -98.55
21 Day Moving AverageUS$ 1.509
21 Day Extended Moving AverageUS$ 1.5083
50 Day Moving AverageUS$ 1.7984
50 Day Extended Moving AverageUS$ 1.8179
200 Day Moving AverageUS$ 4.5654
200 Day Extended Moving AverageUS$ 9.395
10 Day Average Volume235,859
20 Day Average Volume211,031
30 Day Average Volume222,332
50 Day Average Volume244,095
Alpha-0.009360
Beta1.2386
Standard Deviation0.352680
R20.036983
7 Day Price ChangeUS$ 0.04
7 Day Percent Change3.1%
21 Day Price ChangeUS$ -0.38
21 Day Percent Change-22.22%
30 Day Price ChangeUS$ -0.43
30 Day Percent Change-24.43%
Month to Date Price ChangeUS$ -0.43
Month to Date Percent Change-24.43%
Quarter to Date Price ChangeUS$ -0.89
Quarter to Date Percent Change-40.09%
180 Day Price ChangeUS$ -4.86
180 Day Percent Change-78.51%
200 Day Price ChangeUS$ -3.46
200 Day Percent Change-72.23%
Year to Date Price ChangeUS$ -11.29
Year to Date Percent Change-89.46%

Quince Therapeutics Inc. (QNCX) Key Ratios

PROFITABILITY
EBIT Margin0.0%
EBITDA Margin0.0%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
RevenueUS$ 0
Revenue Per ShareUS$ 0.00
Revenue (3 Years)US$ 0.00
Revenue (5 Years)US$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book0.50
Total Debt To Equity0.00
Int Coverage0.00
Current Ratio16.70
Leverage Ratio1.10
Quick Ratio16.30
Long Term Debt To Capital0.00
VALUATION MEASURES
PE Ratio-0.50
Enterprise ValueUS$ -46,121,508
Price to Sales0.00
Price to Free Cash-1.40
PE High Last 5 Years0.00
Price To Book0.40
Price To Cash Flow0.00
PE Low Last 5 Years0.00
Price to Tangible Book0.50
MANAGEMENT EFFECTIVENESS
Receivables Turnover0.00
Invoice Turnover0.00
Assets Turnover0.00
Return Assets-59.67
Return on Equity-65.70
Return on Capital-65.62

Quince Therapeutics Inc. (QNCX) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorBDO USA, LLP
CEODirk Thye
Emplyoees55
Last AuditUQ
CIK0001662774
IndustryBiotechnology
SectorHealthcare
NAICSPharmaceutical Preparation Manufacturing(325412)
CONTACT INFO
Address269 East Grand Avenue
Suite 1250
South San Francisco, CA 94080
Websitehttps://www.cortexyme.com
Facsimile-
Telephone+1 415 910-5717
Email-
Your Recent History
NASDAQ
QNCX
Quince The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now
NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:ca D:20221003 12:24:52